Trial Profile
A Study to Evaluate the Safety and Effectiveness of Mobilizing Hematopoietic Stem/Progenitor Cells (HSPCs) with G-CSF + Plerixafor in Patients Affected by Βeta-Thalassemia Major
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Plerixafor (Primary)
- Indications Thalassaemia
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology